Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577557 | 0.87 | SCN2A (0.46) | DRD2DRD3GAASMN1; SMN2ACKR3 | |
| SCHEMBL5577709 | 0.86 | GAA (0.51) | GAASMN1; SMN2MAPTNPC1LMNA | |
| SCHEMBL5577657 | 0.86 | GNRHR (0.45) | DRD2DRD3DRD4GAATP53 | |
| SCHEMBL5577774 | 0.86 | LMNA (0.43) | DRD2DRD3DRD4GAALMNA | |
| SCHEMBL5577602 | 0.85 | SMN1; SMN2 (0.48) | GAASMN1; SMN2TP53MAPTLMNA | |
| SCHEMBL5577511 | 0.84 | ACKR3 (0.49) | DRD2DRD3DRD4GAASMN1; SMN2 | |
| SCHEMBL5577320 | 0.83 | DRD2 (0.58) | DRD2DRD3DRD4GAASMN1; SMN2 | |
| SCHEMBL5577798 | 0.82 | GAA (0.46) | GAASMN1; SMN2MAPTLMNAL3MBTL1 | |
| SCHEMBL5577418 | 0.81 | GAA (0.45) | GAASMN1; SMN2MCHR1L3MBTL1 | |
| SCHEMBL5577800 | 0.81 | GAA (0.45) | GAASMN1; SMN2LMNAMCHR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | DRD2 4468/4885DRD3 4080/4885DRD4 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.